<DOC>
	<DOCNO>NCT00771420</DOCNO>
	<brief_summary>Investigate safety tolerability escalate dose CAM-3001 patient .</brief_summary>
	<brief_title>A Single Dose Study CAM-3001 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>To investigate safety tolerability escalate single dos CAM-3001 patient RA ; To investigate pharmacokinetics single dos CAM-3001 RA patient ; To investigate pharmacodynamics single dos CAM-3001 RA patient ; To investigate preliminary clinical effect CAM-3001 sign symptom RA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed date informed consent , prior study related procedure Male female patient age 1870 year screen visit Use appropriate method contraception A diagnosis adult onset rheumatoid arthritis least 6 month duration define 1987 ACR classification criterion ACR functional class I , II III Treatment methotrexate least 3 month stable dose 10mg 25mg / week ≥ 8 week prior baseline visit Availability clear chest Xray ( i.e . evidence TB , chest infection cardiac failure ) . Patients clinically asymptomatic minor change consistent rheumatoid lung acceptable . Stable mild inactive rheumatoid arthritis opinion investigator unlikely change patient 's therapeutic regimen would require subsequent 3 month . DAS28 ≤ 4.8 least 3 month prior baseline visit Relating RA Diagnosis inflammatory arthritis ( e.g . psoriatic arthritis ankylose spondylitis ) , diagnosis secondary , noninflammatory type arthritis ( e.g . osteoarthritis fibromyalgia ) Investigator 's opinion symptomatic enough interfere evaluation effect CAM3001 patient 's primary diagnosis rheumatoid arthritis Relating Previous Clinical Trials Biologic Therapies Administration investigational experimental nonbiologic therapy 12 week prior baseline visit Administration biologic therapy within 6 month prior baseline visit Relating Concomitant Medications Use prohibit concomitant medication , might confound interpretation study data Relating Medical History Female patient pregnant breastfeeding , plan become pregnant trial 24 week administration CAM3001 Male female patient willing use reliable method birth control duration study A history TB , clinical/radiographic evidence TB , positive TB test A history current symptom sign chronic infection , recent ( within 6 month prior screen visit ) serious infection include herpes zoster Patients high risk infection e.g . history infect joint prosthesis time prosthesis still situ , leg ulcer , indwell urinary catheter , persistent recurrent chest infection Neutrophil count &lt; 1000 x 106 cells/L A positive hepatitis B surface antigen test and/or hepatitis C antibody test result A positive test human immunodeficiency virus ( HIV ) infection Receipt live ( attenuate ) vaccine within 4 week prior baseline study Current recent history significant renal , hepatic , haematological , immunological ( RA ) , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral disease would interfere patient 's participation trial . Patients mild stable asthma mild stable Chronic Obstructive Pulmonary Disease ( COPD ) may include discretion Investigator Active malignancy lymphoproliferative disorder type , history malignancy except basal cell carcinoma skin excise prior screen visit Suspected alcohol substance abuse Donation ≥ 400mL blood within 8 week prior baseline Any significant medical condition opinion investigator might increase risk patient confound interpretation data Individuals legally institutionalise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>